Pharmacological therapies for pain in Parkinson’s disease – a review paper

References

• O’Sullivan SS, Williams DR, Gallagher DA, et al. Nonmotor symptoms as presenting complaints in Parkinson’s disease: a clinicopathological study. Mov Disord. 2008;23:101–106.
   PubMed Web of Science ®Google Scholar
• Broen MP, Braaksma MM, Patijn J, et al. Prevalence of pain in Parkinson’s disease: a systematic review using the modified QUADAS tool. Mov Disord. 2012;27:480–484.
   PubMed Web of Science ®Google Scholar
• Chaudhuri K, Prieto‐Jurcynska C, Naidu Y, et al. The nondeclaration of nonmotor symptoms of Parkinson’s disease to health care professionals: an international study using the nonmotor symptoms questionnaire. Mov Disord. 2010;25:704–709.
   PubMed Web of Science ®Google Scholar
• Rana AQ, Kabir A, Jesudasan M, et al. Pain in Parkinson’s disease: analysis and literature review. Clin Neurol Neurosurg. 2013;115:2313–2317.
   PubMed Web of Science ®Google Scholar
• Brefel-Courbon C, Payoux P, Thalamas C, et al. Effect of levodopa on pain threshold in Parkinson’s disease : a clinical and positron emission tomography study. Mov Disord. 2005;20:1557–1563.
   PubMed Web of Science ®Google Scholar
• Gerdelat-Mas A, Simonetta-Moreau M, Thalamas C, et al. Levodopa raises objective pain threshold in Parkinson’s disease: a RIII reflex study. J Neurol Neurosurg Psychiatry. 2007;78:1140–1142.
   PubMed Web of Science ®Google Scholar
• Slaoui T, Mas-Gerdelat A, Ory-Magne F, et al. [Levodopa modifies pain thresholds in Parkinson’s disease patients]. Rev Neurol. 2007;163:66–71.
   PubMed Web of Science ®Google Scholar
• Nebe A, Ebersbach G. Pain intensity on and off levodopa in patients with Parkinson’s disease. Mov Disord. 2009;24:1233–1237.
   PubMed Web of Science ®Google Scholar
• Gierthmuhlen J, Arning P, Binder A, et al. Influence of deep brain stimulation and levodopa on sensory signs in Parkinson’s disease. Mov Disord. 2010;25:1195–1202.
   PubMed Web of Science ®Google Scholar
• Schestatsky P, Kumru H, Valls-Sole H, et al. Neurophysiologic study of central pain in patients with Parkinson disease. Neurol. 2007;69:2162–2169.
   PubMed Web of Science ®Google Scholar
• Perrotta A, Serrao M, Bartolo M, et al. Abnormal head nociceptive withdrawal reaction to facial nociceptive stimuli in Parkinson’s disease. Clin Neurophysiol. 2005;116:2091–2098.
   PubMed Web of Science ®Google Scholar
• Litvinenko IV, Odinak MM, Mogil’naia VI, et al. [Direct switch from conventional levodopa to stalevo (levodopa/carbidopa/entacapone) improves quality of life in Parkinson’s disease: results of an open-label clinical study]. Zhurnal Nevrologii I Psikhiatrii Imeni SS Korsakova/Ministerstvo Zdravookhraneniia I Meditsinskoi Promyshlennosti Rossiiskoi Federatsii, Vserossiiskoe Obshchestvo Nevrologov [I] Vserossiiskoe Obshchestvo Psikhiatrov. 2009;109:51–54.
   PubMedGoogle Scholar
• Levin OS, Ivanov AK, Shindriaeva NN. [Treatment of non-motor fluctuations with combined drug stalevo in patients with Parkinson’s disease]. Zhurnal Nevrologii I Psikhiatrii Imeni SS Korsakova/Ministerstvo Zdravookhraneniia I Meditsinskoi Promyshlennosti Rossiiskoi Federatsii, Vserossiiskoe Obshchestvo Nevrologov [I] Vserossiiskoe Obshchestvo Psikhiatrov. 2010;111:38–42.
   Google Scholar
• Barone P, Poewe W, Albrecht S, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9:573–580.
   PubMed Web of Science ®Google Scholar
• Stuginski-Barbosa J, Rodrigues GGR, Bigal ME, et al. Burning mouth syndrome responsive to pramipexol. J Headache and Pain. 2008;9:43–45.
   PubMed Web of Science ®Google Scholar
• Rascol O, Zesiewicz T, Chaudhuri K, et al. A randomized controlled exploratory pilot study to evaluate the effect of rotigotine transdermal patch on parkinson’s disease–associated chronic pain. J Clin Pharmacol. 2016;56:852–861.
   PubMed Web of Science ®Google Scholar
• Katzenschlager R, Head J, Schrag A, et al. Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. Neurol. 2008;71:474–480.
   PubMed Web of Science ®Google Scholar
• Dellapina E, Gerdelat‐Mas A, Ory‐Magne F, et al. Apomorphine effect on pain threshold in Parkinson’s disease: a clinical and positron emission tomography study. Mov Disord. 2011;26:153–157.
   PubMed Web of Science ®Google Scholar
• Roggenkamper P, Jost WH, Bihari K, et al. Efficacy and safety of a new botulinum toxin type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm. 2006;113:303–312.
   PubMed Web of Science ®Google Scholar
• Pacchetti C, Albani G, Martignoni E, et al. “Off” painful dystonia in Parkinson’s disease treated with botulinum toxin. Mov Disord. 1995;10:333–336.
   PubMed Web of Science ®Google Scholar
• Madeo G, Schirinzi T, Natoli S, et al. Efficacy and safety profile of prolonged release oxycodone in combination with naloxone (OXN PR) in Parkinson’s disease patients with chronic pain. J Neurol. 2015;262:2164–2170.
   PubMed Web of Science ®Google Scholar
• Trenkwalder C, Chaudhuri KR, Martinez-Martin P, et al. Prolonged-release oxycodone–naloxone for treatment of severe pain in patients with Parkinson’s disease (PANDA): a double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2015;14:1161–1170.
   PubMed Web of Science ®Google Scholar
• Djaldetti R, Yust-Katz S, Kolianov V, et al. The effect of duloxetine on primary pain symptoms in Parkinson disease. Clin Neuropharmacol. 2007;30:201–205.
   PubMed Web of Science ®Google Scholar
• Olanow CW, Kieburtz K, Odin P, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson’s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol. 2014;13:141–149.
   PubMed Web of Science ®Google Scholar
• Deuschl G, Schade-Brittinger C, Krack P, et al. A randomized trial of deep-brain stimulation for Parkinson’s disease. N Engl J Med. 2006;355:896–908.
   PubMed Web of Science ®Google Scholar
• Dellapina E, Ory-Magne F, Regragui W, et al. Effect of subthalamic deep brain stimulation on pain in Parkinson’s disease. Pain. 2012;153:2267–2273.
   PubMed Web of Science ®Google Scholar
• Jung YJ, Kim HJ, Jeon BS, et al. An 8-year follow-up on the effect of subthalamic nucleus deep brain stimulation on pain in Parkinson disease. JAMA Neurol. 2015;72:504–510.
   PubMed Web of Science ®Google Scholar
• Trepanier LL, Kumar R, Lozano AM, et al. Neuropsychological outcome of GPi pallidotomy and GPi or STN deep brain stimulation in Parkinson’s disease. Brain and Cognit. 2000;42:324–347.
   PubMed Web of Science ®Google Scholar
• Cobacho N, José L, González-Escalada JR, et al. Levodopa analgesia in experimental neuropathic pain. Brain Res Bull. 2010;83:304–309.
   PubMed Web of Science ®Google Scholar
• Tinazzi M, Del Vesco C, Defazio G, et al. Abnormal processing of the nociceptive input in Parkinson’s disease: a study with CO2 lazer evoked potentials. Pain. 2008;136:117–124.
   PubMed Web of Science ®Google Scholar
• Tinazzi M, Recchia S, Simonetto S, et al. Hyperalgesia and laser evoked potentials alterations in hemiparkinson: evidence for an abnormal nociceptive processing. J Neurol Sci. 2009;276:153–158.
   PubMed Web of Science ®Google Scholar
• Tinazzi M, Recchia S, Simonetto S, et al. Muscular pain in Parkinson’s disease and nociceptive processing assessed with CO2 laser-evoked potentials. Mov Disord. 2010;25:213–220.
   PubMed Web of Science ®Google Scholar
• Trenkwalder C, Kies B, Rudzinska M, et al. Rotigotine effects on early morning motor function and sleep in Parkinson’s disease: A double‐blind, randomized, placebo-controlled study (RECOVER). Mov Disord. 2011;26:90–99.
   PubMed Web of Science ®Google Scholar
• Trenkwalder C, Kohnen R, Högl B, et al. Parkinson’s disease sleep scale—validation of the revised version PDSS‐2. Mov Disord. 2011;26:644–652.
   PubMed Web of Science ®Google Scholar
• Katunina EA, Titova NV, Bezdolny YN, et al. [Dopamine receptor agonists: new forms and new possibilities in the treatment of Parkinson’s disease]. Zhurnal Nevrologii I Psikhiatrii Imeni SS Korsakova/Ministerstvo Zdravookhraneniia I Meditsinskoi Promyshlennosti Rossiiskoi Federatsii, Vserossiiskoe Obshchestvo Nevrologov [I] Vserossiiskoe Obshchestvo Psikhiatrov. 2014;115:34–40.
   Google Scholar
• Coelho M, Ferreira J, Rosa M, et al. Treatment options for non-motor symptoms in late-stage Parkinson’s disease. Expert Opin Pharmacother. 2008;9:523–535.
   PubMed Web of Science ®Google Scholar
• Factor SA, Brown DL, Molho ES. Subcutaneous apomorphine injections as a treatment for intractable pain in Parkinson’s disease. Mov Disord. 2000;15:167–169.
   PubMed Web of Science ®Google Scholar
• Frankel JP, Lees AJ, Kempster PA, et al. Subcutaneous apomorphine in the treatment of Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1990;53:96–101.
   PubMed Web of Science ®Google Scholar
• Martinez‐Martin P, Rodriguez‐Blazquez C, Kurtis MM, et al. The impact of non‐motor symptoms on health‐related quality of life of patients with Parkinson’s disease. Mov Disord. 2011;26:399–406.
   PubMed Web of Science ®Google Scholar
• Martinez‐Martin P, Reddy P, Katzenschlager R, et al. EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson’s disease. Mov Disord. 2015;30:510–516.
   PubMed Web of Science ®Google Scholar
• Jankovic J. Disease-oriented approach to botulinum toxin use. Toxicon. 2009;54:614–623.
   PubMed Web of Science ®Google Scholar
• Jankovic J, Stacy M. Medical management of levodopa-associated motor complications in patients with Parkinson’s disease. CNS Drugs. 2007;21:677–692.
   PubMed Web of Science ®Google Scholar
• Rana AQ, Ahmed US, Chaudry ZM, et al. Parkinson’s disease: a review of non-motor symptoms. Expert Rev Neurother. 2015;15:549–562.
   PubMed Web of Science ®Google Scholar
• Bartels EM, Juhl CB, Christensen R, et al. Aquatic exercise for the treatment of knee and hip osteoarthritis. Cochrane Database Syst Rev. 2016;23:CD005523.
   Google Scholar
• de Tommaso M, Kunz M, Valeriani M. Therapeutic approach to pain in neurodegenerative diseases: current evidence and perspectives. Expert Rev of Neurother. 2017;17:143–153.
   PubMed Web of Science ®Google Scholar
• Innes KE, Selfe TK, Agarwal P. Prevalence of restless legs syndrome in North American and Western European populations: a systematic review. Sleep Med. 2011;12:623–634.
   PubMed Web of Science ®Google Scholar
• Oertel W, Eggert K, Pahwa R, et al. Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson’s disease (EASE LID 3). Move Disord. 2017. DOI:10.1002/mds.27131.
   Google Scholar